Dr Reddys Laboratories (RDY) Non-Current Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted Non-Current Assets of $2.9 billion for Q2 2026, down 3.93% on a QoQ basis from $3.0 billion in Q1 2026, and little changed year-over-year from $2.9 billion in Q2 2025.
Analysis
Dr Reddys Laboratories (RDY) Non-Current Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories has reported Non-Current Assets for 18 years, with the latest figure at $2.9 billion in Q2 2026.
- On a quarterly basis, Non-Current Assets changed 0.07% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 0.07% change from a year earlier, with the FY2026 full-year figure at $3.0 billion, up 3.94% from the prior year.
- Non-Current Assets was $2.9 billion for Q2 2026 at Dr Reddys Laboratories, down from $3.0 billion in the prior quarter.
- The five-year high for Non-Current Assets was $3.0 billion in Q1 2026, with the low at $1.4 billion in Q4 2022.
- Average Non-Current Assets over 5 years is $2.1 billion, with a median of $1.7 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets slipped 9.42% in 2022, then soared 67.37% in 2024.
- Over 5 years, Non-Current Assets stood at $1.4 billion in 2022, then gained by 15.4% to $1.6 billion in 2023, then jumped by 67.37% to $2.7 billion in 2024, then gained by 10.33% to $3.0 billion in 2025, then dropped by 2.17% to $2.9 billion in 2026.
- The last three Non-Current Assets figures came in at $2.9 billion (Q2 2026), $3.0 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 26.10 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 24.99 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 2.92 Bn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 1.83 Bn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 18.27 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 1.04 Bn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 668.68 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 1.11 Bn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 3.25 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | 18.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.92 Bn |
| Mar 31, 2026 | 3.03 Bn |
| Dec 31, 2025 | 2.98 Bn |
| Sep 30, 2025 | 3.01 Bn |
| Jun 30, 2025 | 2.92 Bn |
| Mar 31, 2025 | 2.80 Bn |
| Dec 31, 2024 | 2.70 Bn |
| Sep 30, 2024 | 2.60 Bn |
| Jun 30, 2024 | 1.75 Bn |
| Mar 31, 2024 | 1.68 Bn |
| Dec 31, 2023 | 1.61 Bn |
| Sep 30, 2023 | 1.56 Bn |
| Jun 30, 2023 | 1.52 Bn |
| Mar 31, 2023 | 1.43 Bn |
| Dec 31, 2022 | 1.40 Bn |
| Sep 30, 2022 | 1.45 Bn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.54 Bn |
| Sep 30, 2021 | 1.56 Bn |